NCT00683449 - Study Evaluating the Safety and Effects of MN-221 in Subjects Experiencing an Acute Exacerbation of Asthma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

March 31, 2009

Study Completion Date

March 31, 2009

Conditions

AsthmaStatus Asthmaticus

Interventions

DRUG

Dose Group 1

IV infusion of MN-221 16 mcg/min for 15 min; total dose of 240 mcg

DRUG

MN-221 placebo

i.v. infusion of placebo for 15 minutes

DRUG

Dose Group 2

i.v. infusion of MN-221 30 mcg/min for 15 minutes (total dose of 450 mcg)

DRUG

Dose Group 3

i.v. infusion of MN-221 16 mcg/min for 15 minutes followed by 8 mcg/min for 105 minutes (total dose = 1,080 mcg)

Trial Locations (9)

Long Island Jewish Medical Center, New Hyde Park

New York Methodist Hospital, Brooklyn

Albert Einstein Medical Center, Philadelphia

MetroHealth Medical Center, Cleveland

Henry Ford Health System, Detroit

Washington University School of Medicine; Div. of Emergency Medicine, St Louis

Maricopa Medical Center; Dept. of Emergency Medicine, Phoenix

LAC + USC Medical Center, Los Angeles

Olive View - UCLA Medical Center, Sylmar